GlassScriptPhysician profile
Mark D Castellani
NPI 1598763542
$3,651.49
in general payments reported to CMS, 2019-2025
23 companies · $20.56 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $236 · 2021: $237 · 2022: $1,060 · 2023: $708 · 2024: $395 · 2025: $20.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,167.05 | 2019-2023 | Tendril, Gallant, Aveir |
| Boston Scientific Corporation | $458.25 | 2019-2024 | Watchman Access System, Watchman Flx, Watchman |
| Janssen Pharmaceuticals, INC | $321.08 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $276.17 | 2019-2021 | |
| Medtronic, INC. | $253.14 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Linq II |
| Medtronic Vascular, INC. | $212.08 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.04 | 2019-2024 | Lifevest |
| Inspire Medical Systems, INC. | $123.15 | 2023-2024 | Inspire |
| Pfizer INC. | $119.86 | 2019-2024 | |
| Abiomed | $115.67 | 2024 | Impella |
| Amgen INC. | $99.86 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $74.25 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $55.04 | 2022-2023 | Andexxa, Brilinta |
| Teleflex LLC | $41.80 | 2021-2023 | Manta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.99 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $30.07 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $25.76 | 2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $21.19 | 2019 | |
| Elutia, INC. | $20.77 | 2021 | |
| Biotronik INC. | $19.48 | 2020 | |
| Bardy Diagnostics, INC. | $17.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Castellani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.